Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin

• Authors: Joanna Kufel-Grabowska
• Languages of publication: EN

Abstracts

EN

Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.

Keywords

EN

breast cancer; complications of oncological therapy; non-pegylated liposomal doxorubicin

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2015
• Volume: 5
• Issue: 3
• Pages: A103-108

Contributors

author

Joanna Kufel-Grabowska

• Greater Poland Cancer Centre, Poznań, Poland

References

• 1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
• 2. Patnaik JL, Byers T, DiGiuseppe C et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer – a retrospective cohort study. Breast Cancer Research 2011; 13: R64.
• 3. Goldhirch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: Highlights of the St.
• Gallen International Expert Consensus on The Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
• 4. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
• 5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J 2001; 344: 783-792.
• 6. Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
• 7. Amant F, von Minckwitz G, Han SN et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol 2013; 31: 2532-2539.
• 8. Batist G, Harris L, Azarina N et al. Improved anti-tumor response rate with decreased cardiotoxity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who have received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006; 17: 587-595.
• 9. Charakterystyka produktu leczniczego Myocet [online: www.ema.europa.eu].

• Document Type: article